

IDENTIFYING PATIENTS WITH HR+ HER2- EARLY BREAST CANCER

INSTRUCTIONS

Your electronic health record may have reporting capabilities that can be used to identify select patients with HR+ HER2- early breast cancer. Consult your organization if administrative user rights are required to access the reporting solutions. Below are inclusion criteria that could be used to identify patients with early breast cancer.

PLEASE NOTE: A custom report may yield most insights into this patient population.

Inclusion Criteria:

Primary Diagnosis:

C50.011	C50.012	C50.019	C50.111	C50.112	C50.119	C50.211	C50.212	C50.219	C50.311
C50.312	C50.319	C50.411	C50.412	C50.419	C50.511	C50.512	C50.519	C50.611	C50.612
C50.619	C50.811	C50.812	C50.819	C50.911	C50.912	C50.919	C50.01	C50.11	C50.21
C50.31	C50.41	C50.51	C50.61	C50.81	C50.91				

NOT

Secondary Neoplasm:

C78.00	C78.01	C78.02	C78.1	C78.2	C78.30	C78.39	C78.4	C78.5	C78.6
C78.7	C78.80'	C78.89 OR C79.00	C79.01	C79.02	C79.10	C79.11	C79.19	C79.2	
C79.31	C79.32	C79.40	C79.49	C79.51	C79.52	C79.60	C79.61	C79.62	C79.70
C79.71	C79.72	C79.89	C79.82	C79.9					

AND

Gene Expression Profile Procedures:

Oncotype DX: 81519	Breast Cancer Index: 81518
Prosigna CPT: 81520	Mammoprint: 81523
Endo predicts: 81522	

INSTRUCTIONS (continued)

AND

Lab components

HR+ (ER receptor/PR receptor) ER/PR

HER2-

AND

Nodal Status/Staging TNM

AJCC Anatomical Staging	TN (M0)
Stage IIA	T0N1
	T1N1
	T2N0
Stage IIB	T2N1
	T3N0
Stage IIIA	T0N2
	T1N2
	T2N2
	T3N1
Stage IIIB	T3N2
	T4N0
	T4N1
Stage IIIC	T4N2
	Any TN3

AND

CPT procedure codes

19301 Mastectomy, partial

19304 Mastectomy, subcutaneous

19306 Mastectomy, urban type

19303 Mastectomy, simple complete

19305 Mastectomy, radical

19307 Mastectomy, modified radical

Novartis is not responsible for the implementation, testing, and ongoing operation of any EHR tools. If you have any questions pertaining to the use of these guides, please refer to your internal IT/IS department. These tools are not designed for, and have not been demonstrated to meet, any accreditation requirements. The instructions included in this brochure are applicable to the OncoEMR platform and are not guaranteed to work for any other software platforms.

OncoEMR® is a registered trademark of Flatiron Health, Inc.

For more information on how the Novartis HIT Team can collaborate with your organization to identify shared priorities please email: HIT.Novartis@novartis.com